Neuromuscular diseases and botulinum toxin in HOF
Quick facts
- Mechanism
- The toxin acts at the neuromuscular junction; in diseases that already affect this region, the effect can be exaggerated or disproportionate.
- Warning list
- Amyotrophic lateral sclerosis, myasthenia gravis, Lambert-Eaton syndrome, some dystrophies and motor neuron diseases.
- Rule of thumb
- When in doubt, do not inject without an assessment by the neurologist or treating physician.
- Extra care
- Medications that affect neuromuscular transmission and a history of weakness, dysphagia or breathing changes.
Botulinum toxin is one of the most widely used products in orofacial harmonization (HOF), with a safety profile that most professionals know well in healthy patients. But the mechanism that makes it useful, blocking the release of acetylcholine at the junction between nerve and muscle, is exactly the weak point of people with diseases that already affect that system.
In this group, an effect that would be mild in someone else can be disproportionate, and consequences such as generalized weakness or difficulty swallowing or breathing go from a theoretical risk to a real one. This page works as a warning list for the medical history and as a guide to reasoning. It does not define medical management, does not cite doses and does not replace the assessment of the neurologist or the physician who follows the patient.
Why do these diseases change the risk?
A muscle contracts when the nerve releases a chemical messenger (acetylcholine) at the neuromuscular junction. Botulinum toxin blocks that release, which reduces contraction of the treated muscle. In a healthy person, the effect stays local and has a wide safety margin.
In someone with a neuromuscular disease, that margin can be smaller, for three general reasons:
- Reduced functional reserve: the system is already working at its limit, and any additional block weighs more.
- Increased sensitivity to the toxin: some diseases make the patient much more sensitive, even to small volumes.
- Risk of spread with widespread effects: toxin spread to swallowing or breathing muscles has more serious consequences in this group.
Which conditions are on the warning list?
The list below is a starting point for the medical history, not a medical classification. Its purpose is to trigger the question "does this call for a specialist assessment?".
| Condition | Why it deserves a warning |
|---|---|
| Myasthenia gravis | Neuromuscular junction disease; increased sensitivity to the toxin (see myasthenia gravis and botulinum toxin) |
| Lambert-Eaton syndrome | Also affects the neuromuscular junction; risk of exaggerated effect |
| Amyotrophic lateral sclerosis | Progressive motor neuron disease; weakness and breathing and swallowing risk |
| Muscular dystrophies | Muscles already affected; reduced functional reserve |
| Other motor neuron diseases | Similar risk of worsening weakness |
| Severe peripheral neuropathies | Depending on the picture, they may change the response |
| Prior botulism or related conditions | A history that calls for a specialist assessment |
| Muscle weakness without a diagnosis | A symptom that calls for investigation before any toxin |
Some conditions have divergent literature and opinions on use, and the individual picture matters a great deal. That is why the rule for the practice is to refer and wait for the assessment, instead of deciding alone.
What should you ask in the medical history?
The medical history in HOF needs objective questions about neuromuscular function, and not only about known diagnoses, because the patient may not have a name for what they feel.
If any answer is positive, stop and refer for assessment. Record the answers and the decision in the patient record and make it clear, in the consent form, that the toxin requires complete information about neurological diseases.
What about medications that interfere?
Besides diseases, some medications can potentiate the effect of the toxin by affecting neuromuscular transmission. This is the case, for example, with certain antibiotics (see aminoglycosides and botulinum toxin) and some other drugs. The list is longer than what fits on one page, and a patient taking multiple medications should have the list reviewed. When in doubt, ask for the physician's assessment.
What should you do if the condition comes up?
Depending on when the information appears:
For complications in general, see complications with botulinum toxin. For signs of spread in the neck, see dysphagia and altered voice after neck toxin. For the referral flow, see patient referral in HOF.
How do you communicate without scaring or minimizing?
The patient may have had toxin before with no problems and be surprised by the refusal. The conversation should be candid: the toxin is safe for most people, but in their case there is a condition that changes the risk. See saying no to a patient with a contraindication, communicating risk to the patient and explaining botulinum toxin to the patient.
What documentation care is needed?
Document the screening, the answers, the contact with the physician, the decision and the instructions. If the refusal is for a clinical reason, record the reason objectively. See general contraindications in HOF and patient records and documentation in HOF.
And what is Harmy's role?
Harmy does not perform health assessments. It helps in the planning conversation, with an illustrative projection made from a frontal photo, and the Glabella point, for example, lets you visualize the area where toxin is usually discussed. But the projection, an illustrative simulation and not a promise of results, never replaces the medical history, the neuromuscular screening or the decision not to inject.
Frequently asked questions
Can someone with myasthenia gravis receive cosmetic botulinum toxin?
Myasthenia is a condition that calls for great caution and, in general, contraindicates elective use without a specialist assessment. The decision belongs to the neurologist who follows the patient, and the HOF professional should not inject without that clearance.
Does amyotrophic lateral sclerosis contraindicate cosmetic toxin?
ALS progressively affects the muscles, and the toxin can worsen weakness and breathing and swallowing risks. Elective cosmetic use is usually discouraged, and any decision must come from the treating physician.
How do you identify a neuromuscular disease in the medical history?
By asking about muscle weakness, disproportionate tiredness, drooping eyelid, double vision, difficulty swallowing and speaking, prior diagnoses and neurological medications. Positive answers call for a medical assessment before the procedure.
What should you do with a patient who finds out about the disease after the injection?
Document it, suspend further injections, advise on warning signs and contact the treating physician. If there is difficulty breathing or swallowing, or significant weakness, call emergency services.
Harmy images are illustrative simulations generated by AI from the patient's photo to support the conversation between practitioner and patient. They are not a promise of results. Indication, technique, product and volume are solely the decision of the licensed practitioner. This content is for information only and does not replace a clinical assessment.